SCHEMBL6152601

SCHEMBL6152601

C=CCOC(=O)Oc1ccc(C(=O)c2ccc(OC(=O)OCC=C)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ELANE P08246 11/20 0.49
CYP3A4 P08684 1/20 0.43
NPC1 O15118 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SNCA P37840 1/20 0.41
LSS P48449 1/20 0.40
ALDH1A1 P00352 2/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10870487 0.91 CYP3A4 (0.50) CYP3A4NPC1POLBMAPTRAB9A
SCHEMBL9717280 0.88 ALDH1A1 (0.51) CYP3A4NPC1POLBMAPTRAB9A
SCHEMBL10349842 0.87 CYP3A4 (0.41) ELANECYP3A4NPC1POLBMAPT
SCHEMBL6152948 0.86 CYP3A4 (0.46) ELANECYP3A4NPC1POLBMAPT
SCHEMBL9717273 0.84 ALDH1A1 (0.48) ELANECYP3A4NPC1POLBMAPT
SCHEMBL9717293 0.84 HSD17B10 (0.53) ALDH1A1HSD17B10LMNA
SCHEMBL12014962 0.83 SNCA (0.43) ELANECYP3A4NPC1POLBMAPT
SCHEMBL7270769 0.83 THRB (0.44) CYP3A4NPC1POLBMAPTRAB9A
SCHEMBL9174753 0.83 CYP3A4 (0.43) CYP3A4NPC1POLBMAPTRAB9A
SCHEMBL6151946 0.83 ELANE (0.46) ELANECYP3A4NPC1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1511750-A1 PROCESS FOR THE PREPARATION OF FAMCICLOVIR TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-03-09 EP claimed
US-20040266795-A1 Process for the preparation of famciclovir TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-12-30 US claimed
WO-2004099208-A1 PROCESS FOR THE PREPARATION OF FAMCICLOVIR TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-11-18 WO claimed
EP-1556383-A1 PROCESS FOR PREPARING FAMCICLOVIR TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-07-27 EP disclosed
US-20050143400-A1 Process for preparing famciclovir TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-06-30 US disclosed
WO-2005026167-A1 PROCESS FOR PREPARING FAMCICLOVIR TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-03-24 WO disclosed
EP-1511750-A1 PROCESS FOR THE PREPARATION OF FAMCICLOVIR TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-03-09 EP disclosed
US-20040266795-A1 Process for the preparation of famciclovir TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-12-30 US disclosed
WO-2004099208-A1 PROCESS FOR THE PREPARATION OF FAMCICLOVIR TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266795-A1 Process for the preparation of famciclovir ADH1C, CPS1, PAICS ELANE 4317/4885CYP3A4 22/4885NPC1 2217/4885
US-20050143400-A1 Process for preparing famciclovir MTAP, TPMT, RFC1 ELANE 4502/4885CYP3A4 377/4885NPC1 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.